Improve: Integrating Emotion Focused Components Into Psychological Therapy

Anxiety Disorder Clinical Trial

— Improve  

Official title:

The Impact of Integrating Emotion Focused Components Into Psychological Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02822443
• Other study ID #: SNF100019_159425 /1
• Status: Completed
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: August 2019

Study information

• Verified date: September 2019
• Source: University of Bern
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to compare the efficacy of two treatment-as-usual (TAU) conditions: TAU with integration of emotion focused components (EFT) and TAU with focus on self-regulation (SR). Especially the long-term efficacy is evaluated with a focus on differential effects. Moreover, the mechanisms of change of both conditions are investigated.

Description:

Background:

"General Psychotherapy" postulates an ongoing process of including all interventions and concepts relevant for a domain, be they from other approaches to psychotherapy or concepts from basic science. "Psychological Therapy" (PT) is a therapeutic approach largely corresponding to the ideas of General Psychotherapy. It draws mainly on empirically validated interventions from Cognitive Behavior Therapy (CBT) and is based on concepts with a strong basis in academic psychology and neighboring fields. PT is based on explicit individual case conceptualization, reference to general therapeutic factors, and an explicit prescriptive concept for building and maintaining the therapeutic relationship. However the range of emotion-related interventions commonly used in PT is limited when compared with an approach like Emotion Focused Therapy (EFT). EFT appears thus as a suitable complement and enrichment to PT as commonly practiced. However, effects of integrating EFT-based interventions in a way that is close to common integrative practice have not yet been studied.

Objective:

To compare the efficacy of two treatment-as-usual (TAU) conditions: TAU with integration of EFT components and TAU with focus on self-regulation (SR).

Methods:

In Switzerland, a randomized-controlled trail will be carried out in secondary care, comparing the efficacy of TAU - EFT and TAU - SR for adults with major depressive disorder, anxiety disorder or adjustment disorder. Respondents will be followed until 36 months after end of therapy (measures will be taken at baseline, after 8 and after 16 weeks, at the end of therapy after 25 weeks, 6 months, 12 months and 36 months follow-up).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: August 2019
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major Depressive Disorder, Anxiety Disorder or Adjustment Disorder according to DSM-IV as main diagnosis

• Minimum age of 18 years

• Mastery of the German language for being able to undergo a psychotherapy in German

• Written informed consent to participate voluntary in the study

Exclusion Criteria:

• Acute suicidality or immediate threats of self-harm

• Diagnosis or history of a psychotic disorder

• Mood incongruent psychotic symptoms

• Bipolar disorder

• Comorbid chronic organic disorder

• Substance use disorder as a main diagnosis

• Indication for a residential treatment

Related Conditions & MeSH terms

• Adjustment Disorder
• Adjustment Disorders
• Anxiety Disorder
• Anxiety Disorders
• Depressive Disorder
• Disease
• Unipolar Depression

Intervention

Behavioral:
• Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
• Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)
25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions

Locations

Country	Name	City	State
Switzerland	University of Bern	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University of Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in symptom impairment measured by the Brief Symptom Inventory (BSI; Franke, 2000)		After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Primary	Change from baseline in depressive symptoms measured by the Beck Depression Inventory (BDI-II; Hautzinger et al., 2006)		After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Primary	Change from baseline in anxiety symptoms measured by the Beck Anxiety Inventory (BAI; Ehlers & Margraf, 2007)		After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Severity of panic disorder and agoraphobia with the Panic and Agoraphobia Scale (PAS; Bandelow, 1997)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Severity of social phobia measured by the Social Phobia Scale SPS; Stangier et al., 1999)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Severity of social interaction anxiety measured by the Social Interaction Anxiety Scale (SIAS; Stangier et al., 1999)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Severity of anxiety symptoms measured by the Questionnaire for General Anxiety Disorder (GAD-7; Spitzer et al., 2006)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Psychological well-being measured with the WHO Well-Being Index (WHO-5; Henkel et al., 2004)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Health-related quality of life measured with the Short Form Healthy Survey (SF-12; Gandek et al., 1998)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Motivational schemata measured by the Questionnaire for Analysis of Motivational Schemata (FAMOS; grosse Holtforth & Grawe, 2000)		Baseline, end of therapy after 25 weeks
Secondary	Motivational incongruence measured by the Incongruence Questionnaire (K-INK; grosse Holtforth et al., 2003)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Interpersonal problems measured by the Inventory of Interpersonal Problems (IIP-32; Thomas et al., 2011)		Baseline, after 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Personality structure measured by the Operationalized Psychodynamic Diagnosis Structure Questionnaire (OPD-SFK; Ehrenthal et al., 2012)		Baseline, end of therapy after 25 weeks
Secondary	Personality traits measured by the Inventory of Personality Organization (IPO-16; Zimmermann et al., 2013)		Baseline
Secondary	Ambivalence over emotional expressiveness measured by the Ambivalence over the Expression of Emotion Scale (AVEX; Trachsel et al., 2010)		Baseline, end of therapy after 25 weeks
Secondary	Emotional competency measured by the Questionnaire for the self-assessment of emotional competencies (SEK-27; Berking & Znoj, 2008)		Baseline, end of therapy after 25 weeks
Secondary	Generalized expectancies for negative mood regulation measured by the Negative Mood Regulation Scale (NMR-SF; Pfeiffer et al., 2013)		Baseline, end of therapy after 25 weeks
Secondary	Psychological flexibility measured by the Acceptance and Action Questionnaire (Fragebogen zu Akzeptanz und Handeln; FAH-II; Gloster et al., 2013)		Baseline, end of therapy after 25 weeks
Secondary	General self-efficacy measured by the General Self-Efficacy Scale (SWE; Schwarzer & Jerusalem, 1999)		Baseline, end of therapy after 25 weeks
Secondary	Therapy evaluation and outcome expectancies measured by the Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV; Schulte, 2005)		Baseline
Secondary	Social desirability measured by the Balanced Inventory of Desirable Responding (BIDR-K; Winkler et al., 2006)		Baseline
Secondary	Client satisfaction measured by the Brief Global Measure of Client Satisfaction (ZUF-8; Schmidt & Wittmann, 2002)		After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	External assessment of interpersonal personality measured by the Impact Message Inventory (IMI-R; Caspar et al. 2002)		Baseline, end of therapy after 25 weeks
Secondary	External assessment of resources measured by the Bernese Inventory of Resources (REF-F and REF-T; Tröske, 2000)		Baseline, end of therapy after 25 weeks
Secondary	External assessment of positive interpersonal qualities measured by the Inventory of Interpersonal Strengths (IIS; Hatcher & Rogers, 2012)		Baseline, end of therapy after 25 weeks
Secondary	Goal attainment measured by the Goal Attainment Scaling (GAS; Kirusek, 1994)		After 8 weeks, after 16 weeks, end of therapy after 25 weeks, 6 months follow-up, 12 months follow-up and 36 months follow-up
Secondary	Regular quality monitoring with the Bern Post Session Report, Patient and Therapist Version (BPSR-P/T; Flückiger et al. 2010)		Weekly until 25 weeks
Secondary	Symptom impairment measured by the Symptom Checklist (SCL-9; Bogerts et al., 2001)		Weekly until 25 weeks
Secondary	Implicit motives measured by the Picture-Story-Exercise - Online Version (PSE-O: Bernecker & Jobst, 2013)		Baseline, end of therapy after 25 weeks